Journal: Aesthetic Surgery Journal. Open Forum
Article Title: Serum Sickness After Cosmetic Botulinum Toxin Type A Injections
doi: 10.1093/asjof/ojag027
Figure Lengend Snippet: Timeline representing the development of serum sickness for the patient in our case report. Note that exposure to Botox occurred for four years prior to the development of symptoms.
Article Snippet: This case report and literature review demonstrates a novel case of serum sickness following cosmetic Botox® (onabotulinumtoxin-A, Allergan Aesthetics, an AbbVie company, Irvine, CA) administration, categorizes hypersensitivity reactions according to the Gell and Coombs classification (Types I–IV), explores the role of complexing proteins and formulation excipients, and highlights emerging clinical concerns.
Techniques: